ROCKET PHARMACEUTICALS, INC.RCKTW決算レポート
Nasdaq
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| RTW Investments, LP | 17.40% | 18.2M | ▼ -2.81pp | 2024-12-16 |
| Wellington Management Group LLP | 12.36% | 11.2M | ▲ +2.24pp | 2024-11-08 |
| BlackRock, Inc. | 6.60% | 5.9M | — | 2024-01-29 |
| The Vanguard Group | 6.04% | 5.4M | — | 2024-02-13 |
| STATE STREET CORPORATION | 3.58% | 77.3K | — | 2024-01-22 |
インサイダー取引
Net 90d: −$122.0K · buys $0 / sells $122.0K期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-02-18 | John Militello | See Remarks | Sell (open market) | 1.2K | $3.34 | $3.9K |
| 2026-02-18 | Martin Wilson | General Counsel | Sell (open market) | 1.4K | $3.34 | $4.6K |
| 2026-02-18 | Gaurav Shah | CEO | Sell (open market) | 6.0K | $3.34 | $20.0K |
| 2026-02-13 | Gaurav Shah | CEO | Sell (open market) | 12.3K | $3.31 | $40.7K |
| 2026-02-13 | Martin Wilson | General Counsel | Sell (open market) | 12.3K | $3.31 | $40.6K |
| 2026-02-13 | John Militello | See Remarks | Sell (open market) | 3.7K | $3.31 | $12.3K |
| 2026-02-11 | Martin Wilson | General Counsel | Grant | 311.8K | $0.00 | $0 |
| 2026-02-11 | Gaurav Shah | CEO | Grant | 286.0K | $0.00 | $0 |
| 2026-02-11 | John Militello | See Remarks | Grant | 30.0K | $0.00 | $0 |
| 2026-02-11 | Rizvi Syed Ali-aamir | Chief Medical Officer | Grant | 62.0K | $0.00 | $0 |
1–10 of 12
1 / 2 ページ